These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 3668249

  • 1. Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives.
    Cruickshank JM, Pennert K, Sörman AE, Thorp JM, Zacharias FM, Zacharias FJ.
    J Hypertens; 1987 Aug; 5(4):489-98. PubMed ID: 3668249
    [Abstract] [Full Text] [Related]

  • 2. Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol).
    Cruickshank JM.
    Drugs Exp Clin Res; 1990 Aug; 16(3):133-6. PubMed ID: 2387213
    [Abstract] [Full Text] [Related]

  • 3. The efficacy and tolerability of antihypertensive treatment based on atenolol in the prevention of stroke and the regression of left ventricular hypertrophy.
    Cruickshank JM, Higgins TJ, Pennert K, Thorp JM, Zacharias FM, Zacharias FJ.
    J Hum Hypertens; 1987 Sep; 1(2):87-93. PubMed ID: 3506623
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D.
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [Abstract] [Full Text] [Related]

  • 5. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
    Bangalore S, Messerli FH, Franklin SS, Mancia G, Champion A, Pepine CJ.
    Eur Heart J; 2009 Jun; 30(11):1395-401. PubMed ID: 19351690
    [Abstract] [Full Text] [Related]

  • 6. The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
    Hansson L.
    J Hypertens Suppl; 1999 Feb; 17(1):S9-13. PubMed ID: 10340838
    [Abstract] [Full Text] [Related]

  • 7. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P, Dorigatti F, Mugellini A, Spagnuolo V, Varì N, Ferrara R, Bertocchi F.
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T, Linjer E, Hedner T, Lanke J, De Faire U, Wester PO, Dahlöf B, Scherstén B.
    Blood Press; 2004 Sep; 13(3):137-41. PubMed ID: 15223721
    [Abstract] [Full Text] [Related]

  • 9. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB, de Faire U, Fyhrquist F, Harris KE, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Hille DA, Dahlöf B.
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [Abstract] [Full Text] [Related]

  • 10. Stroke and coronary heart disease in treated hypertension -- a prospective cohort study over three decades.
    Almgren T, Persson B, Wilhelmsen L, Rosengren A, Andersson OK.
    J Intern Med; 2005 Jun; 257(6):496-502. PubMed ID: 15910553
    [Abstract] [Full Text] [Related]

  • 11. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ, Ishola DA, Akintomide AO, Ajayi AA.
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [Abstract] [Full Text] [Related]

  • 12. Postprandial hypotension predicts all-cause mortality in older, low-level care residents.
    Fisher AA, Davis MW, Srikusalanukul W, Budge MM.
    J Am Geriatr Soc; 2005 Aug; 53(8):1313-20. PubMed ID: 16078956
    [Abstract] [Full Text] [Related]

  • 13. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y, Tsuchihashi T, Onaka U, Eto K, Ueno M.
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [Abstract] [Full Text] [Related]

  • 14. Blood pressure levels, risk factors and antihypertensive treatments: lessons from the SHEAF study.
    Mallion JM, Genès N, Vaur L, Clerson P, Vaïsse B, Bobrie G, Chatellier G.
    J Hum Hypertens; 2001 Dec; 15(12):841-8. PubMed ID: 11773986
    [Abstract] [Full Text] [Related]

  • 15. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, Muggeo M.
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [Abstract] [Full Text] [Related]

  • 16. Isolated systolic hypertension in the elderly: lessons from clinical trials and future directions.
    Black HR.
    J Hypertens Suppl; 1999 Dec; 17(5):S49-54. PubMed ID: 10706327
    [Abstract] [Full Text] [Related]

  • 17. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.
    Mallion JM, Chamontin B, Asmar R, De Leeuw PW, O'Brien E, Duprez D, O'Rourke MF, Rahn KH, Romero R, Battegay E, Hitzenberger G, Safar ME, REASON Project.
    Am J Hypertens; 2004 Mar; 17(3):245-51. PubMed ID: 15001199
    [Abstract] [Full Text] [Related]

  • 18. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
    Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O.
    J Hypertens; 2003 Aug; 21(8):1563-74. PubMed ID: 12872052
    [Abstract] [Full Text] [Related]

  • 19. Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study.
    Shimamoto K, Fujita T, Ito S, Naritomi H, Ogihara T, Shimada K, Tanaka H, Yoshiike N, J-HEALTH Study Committees.
    Hypertens Res; 2008 Mar; 31(3):469-78. PubMed ID: 18497466
    [Abstract] [Full Text] [Related]

  • 20. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
    Tytus RH, Burgess ED, Assouline L, Vanjaka A.
    Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.